Diluted EPS came in at $-0.07, beat the $-0.10 consensus by $0.03.
Filings will appear here once submitted to SEC EDGAR.
Common questions about Cardiol Therapeutics's Q2 2024 earnings report.
Cardiol Therapeutics (CRDL) reported Q2 2024 earnings on August 12, 2024 before market open.
Cardiol Therapeutics reported diluted EPS of $-0.07 for Q2 2024.
EPS beat the consensus estimate of $-0.10 by $0.03.